Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR3 | P32745 | 9/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4487139 | 1.00 | SSTR3 (0.59) | SSTR3SMN1; SMN2KDM4EGAASCN9A | |
| SCHEMBL4735143 | 1.00 | SSTR3 (0.59) | SSTR3SMN1; SMN2KDM4EGAASCN9A | |
| SCHEMBL4735141 | 1.00 | SSTR3 (0.59) | SSTR3SMN1; SMN2KDM4EGAASCN9A | |
| SCHEMBL4496471 | 0.99 | SSTR3 (0.58) | SSTR3SMN1; SMN2KDM4EGAASCN9A | |
| SCHEMBL4488004 | 0.99 | SSTR3 (0.58) | SSTR3SMN1; SMN2KDM4EGAASCN9A | |
| SCHEMBL4488010 | 0.99 | SSTR3 (0.58) | SSTR3SMN1; SMN2KDM4EGAASCN9A | |
| SCHEMBL4496469 | 0.99 | SSTR3 (0.58) | SSTR3SMN1; SMN2KDM4EGAASCN9A | |
| SCHEMBL4488008 | 0.99 | SSTR3 (0.58) | SSTR3SMN1; SMN2KDM4EGAASCN9A | |
| SCHEMBL4496467 | 0.99 | SSTR3 (0.58) | SSTR3SMN1; SMN2KDM4EGAASCN9A | |
| SCHEMBL14038227 | 0.97 | SSTR3 (0.56) | SSTR3SMN1; SMN2KDM4EGAASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582626-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582626-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582626-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090111798-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. | 2009-04-30 | — | — | US | disclosed |
| US-20090111798-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. | 2009-04-30 | — | — | US | disclosed |
| US-20090111798-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. | 2009-04-30 | — | — | US | disclosed |
| WO-2008073982-A2 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111798-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | HAVCR2, PYGL, HCCS | SSTR3 4729/4885SMN1; SMN2 1958/4885KDM4E 2489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.